Sarepta Therapeutics Inc（SRPT）の財務SRPTSarepta Therapeutics Inc

Sarepta Therapeutics, Inc. (SRPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is PMO Products, accounting for 57.5% of total sales, equivalent to $230.56M. Other significant revenue streams include ELEVIDYS and collaboration and other. Understanding this composition is critical for investors evaluating how SRPT navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Sarepta Therapeutics, Inc. maintains a gross margin of 62.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.03%, while the net margin is -1.22%. These profitability ratios, combined with a Return on Equity (ROE) of -9.48%, provide a clear picture of how effectively SRPT converts its operational activities into shareholder value.

In the context of the broader market, SRPT competes directly with industry leaders such as AGIO and ZYME. With a market capitalization of $1.92B, it holds a leading position in the sector. When comparing efficiency, SRPT's gross margin of 62.59% stands against AGIO's 93.30% and ZYME's 100.00%. Such benchmarking helps identify whether Sarepta Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Sarepta's Q2 product sales were $328.7 million, with Elevidys contributing $98.1 million. The gross margin for Q1 2026 was strong at 85.02%, but total revenue has fallen significantly from previous years, indicating volatility in earnings.